Related Experiment Videos
Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma
F Mizorogi1, J Hiramoto, A Nozato
1Department of Internal Medicine I, Daisan Hospital, Jikei University School of Medicine, Komae, Tokyo.
Insights
Hepatitis C virus (HCV) infection is more common in patients with B-cell non-Hodgkin
Area of Science:
- Hepatology
- Oncology
- Virology
Background:
- Hepatitis C virus (HCV) infection is a potential factor in B-cell lymphoproliferative disorders (LPD).
- Previous studies suggest a link between HCV and LPD, necessitating further investigation.
- Understanding this association is crucial for patient management and treatment strategies.
Purpose of the Study:
- To determine the prevalence of HCV infection in patients with B-cell lymphoproliferative disorders (LPD).
- To clarify the clinical features and outcomes of HCV antibody-positive patients with non-Hodgkin's lymphoma (NHL).
Main Methods:
- Retrospective chart review of patients with B-cell LPD, non-B-cell LPD, and control groups.
- Analysis included patients with chronic lymphocytic leukemia, multiple myeloma, and various types of lymphoma.
- Comparison of HCV prevalence between patient groups and a control group with miscellaneous diseases.
Main Results:
- HCV infection was significantly more prevalent in B-cell NHL patients (17%) compared to non-B-cell NHL (0%) and controls (6.6%).
- HCV-positive B-cell NHL patients showed a higher incidence of primary liver involvement (17.6%).
- Liver-related complications were a frequent cause of death (6/7) in HCV-positive B-cell NHL patients.
Conclusions:
- HCV infection prevalence is elevated in B-cell NHL compared to non-B-cell NHL and controls.
- Primary liver involvement and liver-related mortality are significant concerns in HCV-positive B-cell NHL.
- These findings underscore the importance of screening for HCV in B-cell NHL patients.
Objective:
As a causative role of hepatitis C virus (HCV) in B-cell lymphoproliferative disorders (LPD) has been suggested by several reports, we investigated the prevalence of HCV infection among patients with LPD at our hospital with the aim of clarifying the clinical features and the outcome for HCV antibody-positive patients with non-Hodgkin's lymphoma (NHL).
Methods:
Retrospective chart review.
Patients:
A total of 123 patients with B-cell LPD (4 with chronic lymphocytic leukemia, 17 with multiple myeloma, and 100 with B-cell NHL), 38 patients with non-B-cell LPD (5 with adult T-cell lymphoma, 8 with Hodgkin's disease, and 25 with non-B-cell NHL) and 516 patients with miscellaneous diseases other than liver diseases or LPD (control) were studied.
Results:
HCV infection was detected in 17 of 100 patients with B-cell NHL versus none of 25 patients with non-B-cell NHL (p=0.023) and in 34 patients (6.6%) in the control group with miscellaneous diseases (p=0.0011). In HCV-positive B-cell NHL, primary liver involvement was detected in 3 of 17 patients compared to none of 83 HCV-negative patients (p=0.0019). Intermediate-grade lymphoma (Working Formulation) was the most frequent histology. Eleven of 15 HCV-positive patients achieved complete remission after chemotherapy, and 6 of 7 deaths were caused by liver-related diseases.
Conclusion:
The prevalence of HCV infection was higher in patients with B-cell NHL than in those with non-B-cell NHL and the control group. Primary liver involvement and liver-related causes of death were frequent in HCV-positive patients with B-cell NHL.